Cargando…

Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications

The standard of care for breast cancer has gradually evolved from empirical treatments based on clinical-pathological characteristics to the use of targeted approaches based on the molecular profile of the tumor. Consequently, an increasing number of molecularly targeted drugs have been developed. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Toss, Angela, Piacentini, Federico, Cortesi, Laura, Artuso, Lucia, Bernardis, Isabella, Parenti, Sandra, Tenedini, Elena, Ficarra, Guido, Maiorana, Antonino, Iannone, Anna, Omarini, Claudia, Moscetti, Luca, Cristofanilli, Massimo, Federico, Massimo, Tagliafico, Enrico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114971/ https://www.ncbi.nlm.nih.gov/pubmed/30167082 http://dx.doi.org/10.18632/oncotarget.25810

Ejemplares similares

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials
por: Omarini, Claudia, et al.
Publicado: (2020)

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review
por: Canino, Fabio, et al.
Publicado: (2022)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy
por: Toss, Angela, et al.
Publicado: (2022)

Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy
por: Omarini, Claudia, et al.
Publicado: (2020)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going
por: Omarini, Claudia, et al.
Publicado: (2018)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
por: Omarini, Claudia, et al.
Publicado: (2022)

Characterization of New ATM Deletion Associated with Hereditary Breast Cancer
por: Parenti, Sandra, et al.
Publicado: (2021)

Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe
por: Moscetti, L., et al.
Publicado: (2021)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
por: Omarini, Claudia, et al.
Publicado: (2018)

Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature
por: Isca, Chrystel, et al.
Publicado: (2021)

The Role of Exosomes in Breast Cancer Diagnosis
por: Piombino, Claudia, et al.
Publicado: (2021)

Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies
por: Toss, Angela, et al.
Publicado: (2019)

Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk
por: Tenedini, Elena, et al.
Publicado: (2022)

Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat?
por: Toss, Angela, et al.
Publicado: (2017)

Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study
por: Toss, Angela, et al.
Publicado: (2021)

Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era
por: Toss, A., et al.
Publicado: (2021)

Management of PALB2‐associated breast cancer: A literature review and case report
por: Toss, Angela, et al.
Publicado: (2023)

Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study
por: Isca, Chrystel, et al.
Publicado: (2022)

Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers
por: Toss, Angela, et al.
Publicado: (2021)

Ovarian Cancer: Can Proteomics Give New Insights for Therapy and Diagnosis?
por: Toss, Angela, et al.
Publicado: (2013)

Lifestyle Intervention on Body Weight and Physical Activity in Patients with Breast Cancer Can Reduce the Risk of Death in Obese Women: The EMILI Study
por: Cortesi, Laura, et al.
Publicado: (2020)

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
por: Cerma, Krisida, et al.
Publicado: (2023)

Henoch-schönlein Purpura (HSP) in a patient on Abemaciclib
por: Omarini, Claudia, et al.
Publicado: (2020)

BRCA Detection Rate in an Italian Cohort of Luminal Early-Onset and Triple-Negative Breast Cancer Patients without Family History: When Biology Overcomes Genealogy
por: Toss, Angela, et al.
Publicado: (2020)

Molecular characterization and targeted therapeutic approaches in breast cancer
por: Toss, Angela, et al.
Publicado: (2015)

Personalized Systemic Therapies in Hereditary Cancer Syndromes
por: Mastrodomenico, Luciana, et al.
Publicado: (2023)

Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles
por: Cortesi, Laura, et al.
Publicado: (2021)

Unravelling the Complexity of Inherited Retinal Dystrophies Molecular Testing: Added Value of Targeted Next-Generation Sequencing
por: Bernardis, Isabella, et al.
Publicado: (2016)

iVar, an Interpretation-Oriented Tool to Manage the Update and Revision of Variant Annotation and Classification
por: Castellano, Sara, et al.
Publicado: (2021)

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012)

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!
por: Omarini, Claudia, et al.
Publicado: (2020)

The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study
por: Toss, Angela, et al.
Publicado: (2021)

BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees
por: Cortesi, Laura, et al.
Publicado: (2021)

Are you treating ypN0 patient with adjuvant abemaciclib?
por: Toss, A., et al.
Publicado: (2023)

Male mammary myofibroblastoma: Two case reports and brief review of literature
por: Venturelli, Marta, et al.
Publicado: (2020)

Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
por: Venturelli, Marta, et al.
Publicado: (2018)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2021)

Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review
por: Maur, Michela, et al.
Publicado: (2017)

COVID-related disruption in mammographic screening: a year later
por: Toss, A., et al.
Publicado: (2022)

Immune characterization of breast cancer metastases: prognostic implications
por: Dieci, Maria Vittoria, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t384omg2q97rbl0pufvui29631